For a decade, the most powerful non-statin cholesterol drugs have come with a catch: they had to be injected. That changed with a Food and Drug Administration decision clearing the first oral version of a PCSK9 inhibitor, the class of medicines previously available only as shots for patients whose cholesterol stayed dangerously high despite other treatment. The approval turns a periodic injection into a once-daily tablet, a shift with the potential to widen access to one of the strongest tools for lowering “bad” cholesterol.
What the FDA cleared and when
The agency approved Lipfendra, known generically as enlicitide, as the first oral inhibitor of proprotein convertase subtilisin/kexin type 9, or PCSK9, in a decision announced on July 17, 2026. It is cleared as an addition to diet and exercise to reduce low-density lipoprotein cholesterol, the LDL-C often described as “bad” cholesterol, in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia, an inherited condition that drives cholesterol to high levels from an early age. The approval was granted to Merck Sharp & Dohme.
Until now, several PCSK9 inhibitors have been on the market, but all required injection every few weeks. Lipfendra delivers the same target in a once-daily pill, positioning it for adults who need further LDL-C reduction beyond what statins alone provide.
How PCSK9 inhibitors lower cholesterol
PCSK9 is a protein that regulates how efficiently the liver clears LDL cholesterol from the blood. It binds to LDL receptors on liver cells and marks them for destruction, which leaves fewer receptors available to pull cholesterol out of circulation. By blocking PCSK9, the drug preserves those receptors, allowing the liver to remove more LDL-C and drive blood levels down.
That is a different route from statins, which reduce how much cholesterol the liver produces, and it explains why PCSK9 inhibitors have been reserved largely for people who cannot reach their targets on statins or who cannot tolerate them. High LDL-C usually causes no symptoms, but over time it contributes to plaque buildup in artery walls that can rupture and trigger a heart attack or stroke, which is why the FDA has treated elevated LDL-C as a key modifiable risk factor for the leading cause of death in the country.
What the clinical trials showed
The efficacy and safety of Lipfendra were evaluated in two randomized, double-blind, placebo-controlled trials involving a combined 3,207 adults with hypercholesterolemia who were already taking the highest statin dose they could tolerate. In both studies, the main measurement was the percentage change in LDL-C from the start of treatment to week 24, compared with placebo.
The first trial enrolled adults with established atherosclerotic cardiovascular disease or a high risk of it, starting from an average LDL-C of 96 mg/dL, and found the drug produced an average 56 percent reduction at week 24 relative to placebo. The second trial, in adults with the inherited form of high cholesterol, started from an average LDL-C of 119 mg/dL and showed an average 59 percent reduction. Reductions in that range are broadly comparable to what the injectable PCSK9 inhibitors have delivered, which is the basis for describing the pill as working like the shots.
Side effects and safety profile
In the trial of patients with cardiovascular disease or elevated risk, the frequency of adverse reactions was similar between the Lipfendra and placebo groups. In the trial of patients with the inherited condition, the most common side effects that occurred more often with the drug than with placebo were diarrhea and dizziness. Across both studies, the rates of patients stopping treatment because of side effects were comparable between the drug and placebo, a signal that the tablet was generally well tolerated in the studied populations.
An accelerated review path
Lipfendra was cleared under Priority Review, a designation the FDA uses for treatments that may offer a meaningful advantage over existing options. The application also moved through the Commissioner’s National Priority Voucher pilot program, which is intended to speed the review of therapies aimed at national public-health priorities. Cardiology observers have flagged the approval as a notable step precisely because it removes the injection barrier that has limited uptake of an otherwise potent class of drugs, as the American College of Cardiology noted in its coverage of the decision.
Why an oral option matters
The practical significance of the approval lies less in raw potency than in convenience. Injectable therapies require patients to store, handle and self-administer shots on a schedule, steps that can depress adherence and deter some people from starting a PCSK9 inhibitor at all. A daily pill fits into the same routine as a statin, which could make the strongest tier of cholesterol lowering easier to prescribe and easier to sustain. Whether the tablet’s real-world impact matches that promise will depend on cost, insurance coverage and long-term outcome data, but the approval marks the first time the PCSK9 pathway can be targeted without a needle.
This article was researched and drafted with the assistance of AI and reviewed before publication.
More from Morning Overview
